Pao-Huan Chen1, Shang-Ying Tsai2, Chun-Hung Pan3, Chi-Kang Chang4, Sheng-Shiang Su5, Chiao-Chicy Chen6, Chian-Jue Kuo7. 1. Lecturer,Department of Psychiatry,School of Medicine,College of Medicine,Taipei Medical University and Attending Psychiatrist,Department of Psychiatry and Psychiatric Research Center,Taipei Medical University Hospital,Taiwan. 2. Professor,Department of Psychiatry,School of Medicine,College of Medicine,Taipei Medical University and Attending Psychiatrist,Department of Psychiatry and Psychiatric Research Center,Taipei Medical University Hospital,Taiwan. 3. Attending Psychiatrist,Taipei City Psychiatric Center,Taipei City Hospital and Lecturer,Department of Psychology,National Chengchi University,Taiwan. 4. Attending Psychiatrist,Taipei City Psychiatric Center,Taipei City Hospital,Taiwan. 5. Research Assistant,Taipei City Psychiatric Center,Taipei City Hospital,Taiwan. 6. Professor,Department of Psychiatry, School of Medicine,College of Medicine,Taipei Medical University and Psychiatric Research Center, Taipei Medical University Hospital and Professor,Department of Psychiatry,Mackay Memorial Hospital and Department of Psychiatry,Mackay Medical College,Taiwan. 7. Attending Psychiatrist,Taipei City Psychiatric Center,Taipei City Hospital and Associate Professor,Department of Psychiatry,School of Medicine,College of Medicine,Taipei Medical University,Taiwan.
Abstract
BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder. METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder. RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke. CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.
BACKGROUND: Research on the risk of stroke following the use of mood stabilisers specific to patients with bipolar disorder is limited.AimsIn this study, we investigated the risk of stroke following the exposure to mood stabilisers in patients with bipolar disorder. METHOD: Data for this nationwide population-based study were derived from the Taiwan National Health Insurance Research Database. Among a retrospective cohort of patients with bipolar disorder (n = 19 433), 609 new-onset cases of stroke were identified from 1999 to 2012. A case-crossover study design utilising 14-day windows was applied to assess the acute exposure effect of individual mood stabilisers on the risk of ischaemic, haemorrhagic and other types of stroke in patients with bipolar disorder. RESULTS: Mood stabilisers as a group were significantly associated with the increased risk of stroke in patients with bipolar disorder (adjusted risk ratio, 1.26; P = 0.041). Among individual mood stabilisers, acute exposure to carbamazepine had the highest risk of stroke (adjusted risk ratio, 1.68; P = 0.018), particularly the ischaemic type (adjusted risk ratio, 1.81; P = 0.037). In addition, acute exposure to valproic acid elevated the risk of haemorrhagic stroke (adjusted risk ratio, 1.76; P = 0.022). In contrast, acute exposure to lithium and lamotrigine did not significantly increase the risk of any type of stroke. CONCLUSIONS: Use of carbamazepine and valproic acid, but not lithium and lamotrigine, is associated with increased risk of stroke in patients with bipolar disorder.Declaration of interestNone.